Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

10.1176/appi.ajp.159.1.1

10.3109/15622970309167904

10.1097/00001504-200301000-00006

Tohen M, 1999, Olanzapine HGEH Study Group. Am J Psychiatry, 156, 702

10.1001/archpsyc.57.9.841

10.1001/archpsyc.59.1.62

10.1176/appi.ajp.160.4.741

Segal J, 1998, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol, 21, 176

10.1176/appi.ajp.161.6.1057

10.1176/appi.ajp.159.7.1146

10.4088/JCP.v66n0116

Bowden CL, 1994, The Depakote Mania Study Group. JAMA, 271, 918

Cohen LS, 1988, Statistical power analysis for the behavioral sciences. Hillsdale

10.1002/(SICI)1520-6394(1997)6:1<26::AID-DA4>3.0.CO;2-3

10.1136/bmj.310.6977.452

Arvanitis LA, 1997, The Seroquel Trial 13 Study Group. Biol Psychiatry, 42, 233

Copolov DL, 2000, A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med, 30, 95

10.1097/00004850-200015030-00001

Small JG, 1997, A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry, 54, 549

Mullen J, 2001, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther, 23, 1839

10.4088/JCP.v62n0911

10.1034/j.1399-5618.2002.02229.x

10.1034/j.1399-5618.2003.00051.x

10.1111/j.1399-5618.2004.00115.x

10.1097/01.jcp.0000085410.08426.9a

10.1176/ajp.148.10.1359

10.1097/00004714-200302000-00004

10.1016/S0022-3956(98)00023-5

10.1097/00004583-200210000-00011

Ghaemi S, 2002, Int J Neuropsychopharmacol, 5, S110

10.1034/j.1399-5618.2002.01204.x

10.1159/000082021

10.1097/01.jcp.0000144887.66319.2f